‘De-intergration’ of Sandoz from Novartis expected to include manufacturing cuts

1st February 2019 Uncategorised 0

Novartis had what CEO Vas Narasimhan called a transformative year in manufacturing in 2018 as it closed or sold eight facilities and restructured eight others to be more efficient. But more is in store for manufacturing over the next 18 months as Novartis transforms its generics unit Sandoz into an “autonomous unit within Novartis.”

More: ‘De-intergration’ of Sandoz from Novartis expected to include manufacturing cuts
Source: fierce